NCT03189719 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 373
- group Id
- BG001
- value
- 376
- group Id
- BG002
- value
- 749
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m\^2 IV Q3W and 5-FU 800 mg/m\^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments were administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
- id
- BG000
- title
- Pembrolizumab + SOC
- description
- Participants received placebo to pembrolizumab (saline) IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m\^2 IV Q3W and 5-FU 800 mg/m\^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments were administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
- id
- BG001
- title
- Placebo + SOC
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.8
- value
- 62.8
- group Id
- BG001
- spread
- 9.2
- value
- 62.0
- group Id
- BG002
- spread
- 9.5
- value
- 62.4
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 67
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 124
- title
- Female
- measurements
- group Id
- BG000
- value
- 306
- group Id
- BG001
- value
- 319
- group Id
- BG002
- value
- 625
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 42
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 99
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 315
- group Id
- BG001
- value
- 296
- group Id
- BG002
- value
- 611
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 39
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 21
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 201
- group Id
- BG001
- value
- 199
- group Id
- BG002
- value
- 400
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 7
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 139
- group Id
- BG001
- value
- 139
- group Id
- BG002
- value
- 278
- title
- White
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 14
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 29
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 196
- group Id
- BG001
- value
- 197
- group Id
- BG002
- value
- 393
- title
- Asia
- measurements
- group Id
- BG000
- value
- 177
- group Id
- BG001
- value
- 179
- group Id
- BG002
- value
- 356
- title
- Rest of World
- description
- Participants were stratified according to Geographic Region of enrolling site (Asia versus Rest of World)
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Geographic Region
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 102
- group Id
- BG002
- value
- 201
- title
- Adenocarcinoma
- measurements
- group Id
- BG000
- value
- 274
- group Id
- BG001
- value
- 274
- group Id
- BG002
- value
- 548
- title
- Squamous Cell Carcinoma
- description
- Participants were stratified according to baseline Histology (adenocarcinoma versus squamous cell carcinoma)
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Histology
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 149
- group Id
- BG001
- value
- 150
- group Id
- BG002
- value
- 299
- title
- ECOG PS 0
- measurements
- group Id
- BG000
- value
- 223
- group Id
- BG001
- value
- 225
- group Id
- BG002
- value
- 448
- title
- ECOG PS 1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- ECOG PS 2
- description
- ECOG PS 0 = Fully active, able to carry on all pre-disease performance without restriction), ECOG PS 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, ECOG PS 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours. Participants were stratified according to baseline ECOG PS (0 versus 1).
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Group Performance Status (ECOG PS)
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 373
- group Id
- BG001
- value
- 376
- group Id
- BG002
- value
- 749
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m\^2 IV Q3W and 5-FU 800 mg/m\^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments were administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
- id
- BG000
- title
- Pembrolizumab + SOC
- description
- Participants received placebo to pembrolizumab (saline) IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m\^2 IV Q3W and 5-FU 800 mg/m\^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments were administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
- id
- BG001
- title
- Placebo + SOC
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.8
- value
- 62.8
- group Id
- BG001
- spread
- 9.2
- value
- 62.0
- group Id
- BG002
- spread
- 9.5
- value
- 62.4
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 67
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 124
- title
- Female
- measurements
- group Id
- BG000
- value
- 306
- group Id
- BG001
- value
- 319
- group Id
- BG002
- value
- 625
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 42
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 99
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 315
- group Id
- BG001
- value
- 296
- group Id
- BG002
- value
- 611
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 23
- group Id
- BG002
- value
- 39
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 21
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 201
- group Id
- BG001
- value
- 199
- group Id
- BG002
- value
- 400
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 7
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 139
- group Id
- BG001
- value
- 139
- group Id
- BG002
- value
- 278
- title
- White
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 14
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 29
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 196
- group Id
- BG001
- value
- 197
- group Id
- BG002
- value
- 393
- title
- Asia
- measurements
- group Id
- BG000
- value
- 177
- group Id
- BG001
- value
- 179
- group Id
- BG002
- value
- 356
- title
- Rest of World
- description
- Participants were stratified according to Geographic Region of enrolling site (Asia versus Rest of World)
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Geographic Region
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 102
- group Id
- BG002
- value
- 201
- title
- Adenocarcinoma
- measurements
- group Id
- BG000
- value
- 274
- group Id
- BG001
- value
- 274
- group Id
- BG002
- value
- 548
- title
- Squamous Cell Carcinoma
- description
- Participants were stratified according to baseline Histology (adenocarcinoma versus squamous cell carcinoma)
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Histology
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 149
- group Id
- BG001
- value
- 150
- group Id
- BG002
- value
- 299
- title
- ECOG PS 0
- measurements
- group Id
- BG000
- value
- 223
- group Id
- BG001
- value
- 225
- group Id
- BG002
- value
- 448
- title
- ECOG PS 1
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- ECOG PS 2
- description
- ECOG PS 0 = Fully active, able to carry on all pre-disease performance without restriction), ECOG PS 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, ECOG PS 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours. Participants were stratified according to baseline ECOG PS (0 versus 1).
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Group Performance Status (ECOG PS)
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle